Faeth Therapeutics (FTH) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 146.7% versus a gain of 121.4%. Over five years, IRWD leads with a -72.5% price change compared with -83.7% for FTH. Faeth Therapeutics is the larger company by market cap ($643.9 million vs $619.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | IRWD |
|---|---|---|
| Share price | $24.92 | $3.75 |
| Market cap | $643.94M | $619.65M |
| 1-day change | -7.33% | +3.31% |
| YTD return | +133.55% | +11.28% |
| 1-year return | +121.39% | +146.71% |
| 5-year return | -83.67% | -72.55% |
| P/E ratio (TTM) | — | 4.87 |
| Forward P/E | — | 2.50 |
| EPS (TTM) | $-56.49 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $5.78 |
| 52-week low | $7.45 | $1.41 |
| Distance from 52-week high | -40.87% | -35.12% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +127.41% | +62.67% |
| Average volume | 352.35K | 2.03M |
| Shares outstanding | 25.84M | 165.24M |
| Employees | 29 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed FTH by 25.3 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Healthcare · Biotechnology · 29 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Healthcare · Drug Manufacturers - Specialty & Generic · 100 employees
FTH vs IRWD FAQ
Which is bigger, Faeth Therapeutics or Ironwood Pharmaceuticals?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $643.94M compared with $619.65M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, FTH or IRWD?
IRWD returned +146.71% over the past 12 months, compared with +121.39% for FTH (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Ironwood Pharmaceuticals in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Faeth Therapeutics and Drug Manufacturers - Specialty & Generic for Ironwood Pharmaceuticals.